Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers

Clinical Cancer Research

Volumn 19, Issue 23, 2013, Pages 6633-6643

  Mehra, Ranee ^a   Zhu, Fang ^a   Yang, Dong Hua ^a   Cai, Kathy Q ^a   Weaver, Joellen ^a,b   Singh, Mahendra K ^a,c   Nikonova, Anna S ^a   Golemis, Erica A ^a   Flieder, Douglas B ^a   Cooper, Harry S ^a   Lango, Miriam ^a   Ridge, John A ^a   Burtness, Barbara ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Biovest International Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1 ANTIBODY; PLATINUM COMPLEX; PROTEIN ANTIBODY; PROTEIN P16; UNCLASSIFIED DRUG;

ADJUVANT CHEMORADIOTHERAPY; AGE; ANTIBODY SPECIFICITY; ARTICLE; AUTOMATION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; TISSUE MICROARRAY; WART VIRUS;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HEAD AND NECK NEOPLASMS; HELA CELLS; HUMANS; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84890297022     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0152     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Goldenberg D, Lee J, Koch WM, Kim MM, Trink B, Sidransky D, et al. Habitual risk factors for head and neck cancer. Otolaryngal Head Neck Surg 2004;131:986-93.
3. Herrero R, Castellsague X, Pawlita M. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95:1772-83.
4. Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12.
5. Rischin D, Young R, Fisher R, Fox S, Le Q-T, Peters L, et al. Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. J Clin Oncol 27:15s, 2009 (suppl; abstr 6004).
6. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Sasaki C, et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 2004;10:5684-91.
7. Lingen MW, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P, et al. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol 2013;49:1-8.
8. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamouscell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-51.
9. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
10. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.
11. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapyadded to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.
12. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993;14:2177-80.
13. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94:703-8.
14. Moeller BJ, Yordy JS, Williams MD, Giri U, Raju U, Molkentine DP, et al. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res 2011;17:2035-43.
15. Ahmad A, Robinson AR, Duensing A, Van Drunen E, Beverloo HB, Weisberg DB, et al. ERCC1-XPF endonuclease facilitates DNA doublestrand break repair. Mol Cell Biol 2008;28:5082-92.
16. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006;17:1818-25.
17. Bessho T, Sancar A, Thompson LH, Thelen MP. Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex. J Biol Chem 1997;272:3833-7.
18. Orelli B, McClendon TB, Tsodikov OV, Ellenberger T, Niedernhofer LJ, Scharer OD. The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways. J Biol Chem 2009;285:3705-12.
19. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
20. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013;368:1101-10.
21. Gustavson MD, Bourke-Martin B, Reilly DM, Cregger M, Williams C, Tedeschi G, et al. Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using automated QUantitative analysis. Appl Immunohistochem Mol Morphol 2009;17:329-37.
22. Moeder CB, Giltnane JM, Moulis SP, Rimm DL. Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol 2009;520:163-75.
23. Houtsmuller AB, Rademakers S, Nigg AL, Hoogstraten D, Hoeijmakers JH, Vermeulen W. Action of DNA repair endonuclease ERCC1/XPF in living cells. Science 1999;284:958-61.
24. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007;13:3855-9.
25. Jun. HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 2008;99:167-72.
26. Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 2008;14:4225-31.
27. Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer 2008;44:54-60.
28. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8.
29. Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 2009;28:2903-9.
30. Niedernhofer LJ, Bhagwat N, Wood RD. ERCC1 and non-small-cell lung cancer. N Engl J Med 2007;356:2538-40.
31. Besse B, Olaussen KA, Soria JC. ERCC1 and RRM1: ready for prime time? J Clin Oncol 2013;31:1050-60.
32. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 2009;69:6831-8.
33. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808-15.
34. Van Putten W. CART: Stata module to perform Classification And Regression Tree analysis. Chestnut Hill, MA: Department of Economics, Boston College, 2006.
35. Fountzilas G, Bamias A, Kalogera-Fountzila A, Karayannopoulou G, Bobos M, Athanassiou E, et al. Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. Anticancer Res 2009;29:529-38.
36. Mooradian AD. Biomarkers of aging: do we know what to look for? J Geront 1990;45:B183-6.
37. Miura M, Nakamura S, Sasaki T, Takasaki Y, Shiomi T, Yamaizumi M. Roles of XPG and XPF/ERCC1 endonucleases in UV-induced immunostaining of PCNA in fibroblasts. Exp Cell Res 1996;226:126-32.
38. Hao D, Lau HY, Eliasziw M, Box A, Diaz R, Klimowicz AC, et al. Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status. Head Neck 2011;34:785-91.
39. Seiwert TY, Cohen EE, Wang X, Kocherginsky M, Bhayani M, Stenson K, et al. editors. Use of systematic analysis of DNA repair pathways in head and neck cancer (HNC) to identify XPF as a novel predictor of induction response, and pMK2 relationship to chemoradiotherapy. J Clin Oncol 26:15S, 2008 (suppl; abstr 6003).
40. Austin M, Schmidt R, Parvathaneni U, Bauman J, Hayes D, Papagikos M, et al. editors. Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: a phase II randomized trial. J Clin Oncol 30, 2012 (suppl; abstr 5515).
41. Olaussen KA, Soria JC. Validation of ERCC1-XPF immunodetection-letter. Cancer Res 2010;70:3851-2.
42. Arbogast S, Behnke S, Opitz I, Stahel RA, Seifert B, Weder W, et al. Automated ERCC1 immunohistochemistry in non-small cell lung cancer: comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297. Appl Immunohistochem Mol Morphol 2011;19:99-105.
43. Bhagwat N, Olsen AL, Wang AT, Hanada K, Stuckert P, Kanaar R, et al. XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. Mol Cell Biol 2009;29:6427-37.
44. Murray D, Macann A, Hanson J, Rosenberg E. ERCC1/ERCC4 50-endonuclease activity as a determinant of hypoxic cell radiosensitivity. Int J Radiat Biol 1996;69:319-27.
45. Murray D, Rosenberg E. The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res 1996;364:217-26.
46. Vaezi A, Wang X, Buch S, Gooding W, Wang L, Seethala RR, et al. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res 2011;17:5513-22.